within Pharmacolibrary.Drugs.ATC.M;

model M01AA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 6.666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00013000000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023333333333333335,
    Tlag           = 600,            
    Vdp             = 0.00027,
    k12             = 0.01,
    k21             = 0.01
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties, previously widely used for the treatment of pain and inflammation related to arthritis and gout. Due to its significant side effect profile, especially risk of agranulocytosis and aplastic anemia, its human use is now severely restricted or withdrawn in many countries, though it remains in use in veterinary medicine.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, single oral dose pharmacokinetics</p><h4>References</h4><ol><li><p>Houck, EL, et al., &amp; Delk, KW (2022). Phenylbutazone pharmacokinetics in southern white rhinoceros (Ceratotherium simum simum) after oral administration. <i>Journal of veterinary pharmacology and therapeutics</i> 45(2) 196–202. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13036&quot;>10.1111/jvp.13036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34894412/&quot;>https://pubmed.ncbi.nlm.nih.gov/34894412</a></p></li><li><p>Aarbakke, J (1978). Clinical pharmacokinetics of phenylbutazone. <i>Clinical pharmacokinetics</i> 3(5) 369–380. DOI:<a href=&quot;https://doi.org/10.2165/00003088-197803050-00003&quot;>10.2165/00003088-197803050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/359213/&quot;>https://pubmed.ncbi.nlm.nih.gov/359213</a></p></li><li><p>Knych, HK, et al., &amp; Kass, PH (2019). Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. <i>Drug testing and analysis</i> 11(6) 792–803. DOI:<a href=&quot;https://doi.org/10.1002/dta.2553&quot;>10.1002/dta.2553</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30499176/&quot;>https://pubmed.ncbi.nlm.nih.gov/30499176</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AA01;
